StockData

Ardelyx vs Xeris Biopharma

ARDX and XERS side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.

How ARDX and XERS compare

Xeris Biopharma is the larger company, worth 3.9 times as much as Ardelyx ($3.1B against $792M).

Xeris Biopharma grew revenue faster over the last twelve months (36.3% versus 16.8% for Ardelyx).

Xeris Biopharma keeps more of each dollar of sales as profit, with a net margin of −5.1% compared with −12.4% at Ardelyx.

Xeris Biopharma scores higher on the StockData Score (10 against 9 for Ardelyx), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.

Key numbers

A dot marks the better figure where higher or lower is clearly better.

MetricARDXXERS
Size and price
Market cap$792M$3.1B
Share price$3.18$16.80
Change, 1 year−45.7%134%
Change, 5 years256%674%
Beta (5Y)1.090.27
Employees489435
StockData Score
Total score910 (better)
Valuation score2 (better)0
Growth score34 (better)
Performance score33
Health score13 (better)
Dividend score00
Valuation
P/S1.8× (better)9.1×
P/B5.3×–
EV/EBITDA–84.2×
FCF yield−2.3%–
Fair value$7.61–
Margin of safety58.2%–
Growth
Revenue growth (TTM)16.8%36.3% (better)
Revenue growth, 5Y average122% (better)70.2%
Profitability
Gross margin94.4% (better)86.6%
Operating margin−7.9%10.9% (better)
Net margin−12.4%−5.1% (better)
FCF margin−4.0%–
Return on equity−38.6%–
Return on invested capital–22.1%
Financial health
Net debt / EBITDA–3.45
Interest coverage−1.6×1.3× (better)
Current ratio3.34 (better)1.45
Altman Z-score−0.103.33 (better)
Piotroski F-score38 (better)
Dividends and buybacks
Shareholder yield0.00%0.00%
Ownership
Held by institutions71.2%59.4%
Held by insiders6.9%5.2%
Insider net buying, 12 months−$1.9M (better)−$5.8M
Short interest, % of float12.6%5.2%

Go deeper

For information only, not investment advice. Check the source filings before relying on any figure.